Sotorasib Tablets 120mg (Lumakras® / ルマケラス錠120mg)

JPY ¥282,500

Japanese Antineoplastic Agent / KRAS G12C Inhibitor (Sotorasib 120mg). Oral tablet for KRAS G12C mutation-positive unresectable advanced/recurrent non-small cell lung cancer and colorectal cancer after prior chemotherapy. 56 tablets [8 tablets (PTP) x 7]. Mfd. by Amgen K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥259,900
10 - 19 12% JPY ¥248,600
20 + 18% JPY ¥231,650
SKU: LMK-120-TAB Category:

Description

Product Overview / 商品概要

Lumakras Tablets 120mg (ルマケラス錠120mg)
Generic: Sotorasib / ソトラシブ
Therapeutic Category: Antineoplastic Agent / KRAS G12C Inhibitor / 抗悪性腫瘍剤/KRAS G12C阻害剤
Manufactured by: Amgen K.K. / アムジェン株式会社

Composition & Specification / 組成・規格

Active Ingredient: Sotorasib 120mg per tablet / 1錠中ソトラシブ120mg
Additives: Microcrystalline cellulose, Lactose hydrate, Croscarmellose sodium, Magnesium stearate, Polyvinyl alcohol (partially hydrolyzed), Titanium oxide, Macrogol 4000, Talc, Yellow ferric oxide / 結晶セルロース、乳糖水和物、クロスカルメロースナトリウム、ステアリン酸マグネシウム、ポリビニルアルコール(部分けん化物)、酸化チタン、マクロゴール4000、タルク、黄色三二酸化鉄
Appearance: Yellow film-coated tablet; major axis 16.00mm, minor axis 7.11mm, thickness 5.58mm, weight 618.0mg; identification code: AMG
外観: 色:黄色、剤形:フィルムコーティング錠、長径16.00mm、短径7.11mm、厚さ5.58mm、重量618.0mg、識別コード:AMG

Indications / 効能効果

EN: ○ Unresectable advanced or recurrent non-small cell lung cancer with KRAS G12C mutation that has progressed after cancer chemotherapy
○ Unresectable advanced or recurrent colorectal cancer with KRAS G12C mutation that has progressed after cancer chemotherapy
JA: ○がん化学療法後に増悪したKRAS G12C変異陽性の切除不能な進行・再発の非小細胞肺癌
○がん化学療法後に増悪したKRAS G12C変異陽性の治癒切除不能な進行・再発の結腸・直腸癌

Dosage and Administration / 用法用量

EN: The usual adult dose is 960mg of sotorasib administered orally once daily. Dose reduction should be made as appropriate based on the patient’s condition.
In combination with panitumumab (genetically recombinant), the usual adult dose is 960mg of sotorasib administered orally once daily. Dose reduction should be made as appropriate based on the patient’s condition.
JA: 〈がん化学療法後に増悪したKRAS G12C変異陽性の切除不能な進行・再発の非小細胞肺癌〉通常、成人にはソトラシブとして960mgを1日1回経口投与する。なお、患者の状態により適宜減量する。
〈がん化学療法後に増悪したKRAS G12C変異陽性の治癒切除不能な進行・再発の結腸・直腸癌〉パニツムマブ(遺伝子組換え)との併用において、通常、成人にはソトラシブとして960mgを1日1回経口投与する。なお、患者の状態により適宜減量する。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 30400AMX00014000
Sales Started: April 2022 / 2022年4月
Classification Code: 874291
Storage: Store at room temperature / 室温保存
Shelf Life: 36 months / 36箇月

Packaging / 包装

Main Package (for sale): 56 tablets [8 tablets (PTP) x 7] / 56錠[8錠(PTP)×7]
Other Available Packages (by special order): 56 tablets [8 tablets (PTP) x 7]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Sotorasib Tablets 120mg (Lumakras® / ルマケラス錠120mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Sotorasib Tablets 120mg (Lumakras®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.